Current management strategies for FRDA aim for symptomatic relief and no treatments can prevent disease onset or progression. Thus, research efforts have focused on targeting the molecular pathways that silence FXN and downstream pathological processes. However, progression of potential therapies into clinical use has been hindered by inconclusive clinical trials because of the small patient sample size associated with the low prevalence of this condition. Here, the authors discuss various molecular approaches and explore their therapeutic potential to alter the course of this progressive condition.

Read the Full article here